April 19, 2021 -- Valo Therapeutics has acquired the intellectual property rights to the University of Helsinki's PeptiBAC cancer and infectious disease vaccination technology.
PeptiBAC uses the Bacillus Calmette-Guèrin (BCG) vaccine as its base to deliver disease-specific peptides and shows prophylactic potential for diseases such as tuberculosis and treatment potential for cancer, Valo said. The BCG vaccine is widely used and tolerated, according to the firm.
PeptiBAC elicits antitumor effects and induces tumor specific CD8+ effector T cells and has been shown to increase antitumor response rates in combination with checkpoint inhibitors. Valo plans to use the technology to expand into different cancer indications with its partners.
Financial details of the deal were not disclosed.